CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics, today announced its participation in six upcoming conferences.
